샘플 요청 목록

 카트 문의
시장보고서
상품코드
1565035

세계의 당질체학/당쇄생물학 시장

Glycomics / Glycobiology
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 249 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당질체학/당쇄생물학 세계 시장은 2030년까지 64억 달러에 달할 것

2023년 21억 달러로 추정되는 당질체학/당쇄생물학 세계 시장은 2023-2030년의 분석 기간 동안 연평균 16.9% 성장하여 2030년에는 64억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 효소 부문은 CAGR 17.8%를 기록하여 분석 기간 종료 시점에 29억 달러에 도달할 것으로 예상됩니다. 키트 및 시약 부문의 성장률은 분석 기간 동안 CAGR 16.8%로 추정됩니다.

미국 시장은 약 5억 9,290만 달러, 중국은 CAGR 16.0%로 성장할 것으로 예상

미국의 당질체학/당쇄생물학 시장은 2023년 5억 9,290만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 9억 6,640만 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 16.0%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 14.9%와 14.3%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 약 12.2%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 당질체학/당쇄생물학 시장 - 주요 동향 및 촉진요인 요약

당질체학/당쇄생물학이 생명공학 및 의학의 주요 분야로 부상하고 있는 이유는 무엇일까요?

당사슬 생물학이라고도 불리는 당질체학은 복잡한 생물학적 과정을 이해하고 치료법을 발전시키는 데 중요한 역할을 하기 때문에 생명공학 및 의학에서 없어서는 안 될 분야로 자리 잡고 있습니다. 그렇다면 오늘날 당질체학가 왜 이토록 중요한 것일까? 당쇄생물학은 단백질과 지질에 결합하여 세포 신호전달, 면역반응, 질병 진행 등 다양한 생물학적 기능에 관여하는 복합 당질인 당쇄를 종합적으로 연구하는 학문입니다. 당쇄생물학은 이러한 당분자가 세포 간 소통, 질병 메커니즘, 새로운 진단 및 치료법 개발에 어떻게 영향을 미치는지에 초점을 맞추었습니다.

당사슬은 암, 자가면역질환, 감염성 질환 등 질병의 진행에 중요한 역할을 하기 때문에 당쇄생물학 연구는 인간의 건강에 광범위한 의미를 가지고 있습니다. 연구자들은 당 사슬의 구조와 기능을 해독함으로써 질병을 조기에 진단하고, 보다 표적화된 치료법을 개발하고, 보다 효과적인 백신을 개발할 수 있는 새로운 방법을 발견하고 있습니다. 또한, 당질체학은 약물 상호 작용을 이해하고 생물학적 제제를 설계하는 데 필수적이며, 이는 정밀 의학에서 필수적인 도구가 되고 있습니다. 개인 맞춤형 의료의 중요성이 커짐에 따라, 당질체학은 분자 수준에서 신체 기능에 대한 새로운 통찰력을 제공해 진단, 치료 및 백신 개발의 혁신을 촉진하고 있습니다.

기술의 발전은 어떻게 당질체학의 연구와 응용을 가속화하고 있는가?

기술의 발전은 당 사슬의 복잡성을 해독하고 생물학적 시스템에서 다양한 기능을 밝힐 수 있게 하여 당질체학 연구를 추진하는 데 매우 중요한 역할을 하고 있습니다. 중요한 발전 중 하나는 질량 분석(MS) 및 액체 크로마토그래피(LC)와 같은 고처리량 당쇄 분석 기술의 개발로 당쇄 구조의 신속한 식별 및 특성 분석이 가능해졌습니다. 이러한 도구를 통해 연구자들은 생물체 또는 조직 내 전체 당쇄인 글리칸(glycome)을 전례 없이 빠르고 정확하게 매핑할 수 있게 되었습니다. 이러한 능력은 글리컴이 조직, 개인, 질환에 따라 어떻게 다른지 이해하는 데 매우 중요하며, 보다 맞춤화된 치료법을 위한 길을 열어줄 수 있습니다.

또 다른 중요한 기술 발전은 바이오인포매틱스 도구를 당질체학 연구에 적용하는 것입니다. 수많은 분지와 다양한 구성을 가진 당쇄 구조의 복잡성은 분석과 해석을 위한 고도의 계산 기법을 필요로 합니다. 머신러닝과 인공지능(AI)의 발전으로 당쇄 구조와 단백질 및 지질과의 상호작용을 예측할 수 있는 알고리즘을 개발할 수 있게 되었습니다. 이러한 생물정보학 도구는 연구자들이 질병의 당쇄 바이오마커를 식별하고, 당쇄 기반 치료제를 개발하며, 당쇄의 변화가 질병 진행에 어떻게 관여하는지 밝히는 데 도움이 될 수 있으며, AI 기반 분석을 통해 과학자들은 방대한 양의 당쇄 데이터를 선별할 수 있으며, 패턴과 잠재적 치료 표적을 보다 효율적으로 식별할 수 있습니다.

합성 당쇄생물학의 발전은 합성 당쇄의 설계와 제조를 가능하게 함으로써 이 분야에도 변화를 가져오고 있습니다. 이러한 합성 당쇄는 자연에 존재하는 분자를 모방하여 백신 개발, 신약 개발, 치료 연구에 활용되고 있습니다. 예를 들어, 연구자들은 병원체가 인간 세포와 어떻게 상호작용하는지 연구하거나 강력한 면역 반응을 유발하는 백신을 개발하기 위해 특정 당쇄 구조를 만들어낼 수 있습니다. 이 능력은 당쇄가 면역 회피에 중요한 역할을 하는 독감이나 코로나바이러스와 같은 복잡한 바이러스에 대한 백신을 개발하는 데 특히 중요합니다. 또한, 합성 당쇄는 암세포의 특정 수용체를 표적으로 삼거나 면역 반응을 조절하는 당쇄 기반 약물의 개발에 활용되어 정밀 의학의 새로운 길을 열어가고 있습니다.

또 다른 발전 분야는 극저온 전자 현미경(cryoEM) 및 당쇄 어레이 기술과 같은 첨단 이미징 기술의 활용입니다. 이러한 도구는 당쇄가 다른 생체 분자와 어떻게 상호 작용하는지를 분자 수준에서 시각화할 수 있게 해줍니다. 이는 세포 신호 전달, 병원체 인식, 면역계 기능 등의 과정에서 당쇄의 역할을 이해하는 데 매우 중요합니다. 예를 들어, 당쇄 어레이는 단백질과의 당쇄 상호작용에 대한 높은 처리량 스크리닝을 가능하게 하여 암이나 신경 퇴행성 질환과 같은 질병에 대한 잠재적인 신약 타겟과 바이오마커를 밝혀낼 수 있습니다. 이러한 이미징 및 스크리닝 기술은 건강과 질병에서 당쇄의 역동적인 역할에 대한 더 깊은 통찰력을 제공합니다.

질병 기전 규명, 진단약 개발, 치료법 발전에 당질체학가 필수적인 이유는 무엇일까?

당사슬은 생물학적 과정과 질병의 진행을 조절하는 데 기본적인 역할을 하기 때문에 당질체학은 질병 메커니즘의 이해, 진단법 개발 및 치료법 발전에 필수적입니다. 당 사슬은 단백질의 접힘과 안정성에서 면역 체계 활성화와 세포 간 통신에 이르기까지 세포 기능의 거의 모든 측면에 관여합니다. 당쇄 구조의 변화는 종종 질병 상태와 관련이 있으며, 당질체학은 바이오마커를 식별하고 분자 수준에서 질병 메커니즘을 이해하는 데 귀중한 도구가 되고 있습니다.

당화물이 의학에 기여하는 가장 중요한 공헌 중 하나는 질병의 조기 발견을 위한 바이오마커를 발견하는 능력입니다. 글리코 실화(당 사슬이 단백질과 지질에 결합하는 과정)의 변화는 암, 당뇨병, 감염성 질환과 같은 질병에서 자주 관찰됩니다. 예를 들어, 비정상적인 당쇄 패턴은 암세포의 특징이며, 종양 성장, 전이 및 면역 회피를 촉진할 수 있습니다. 이러한 변화된 당쇄 시그니처를 식별함으로써 연구자들은 보다 민감하고 특이적인 진단 테스트를 개발할 수 있습니다. 당쇄 기반 바이오마커는 질병의 조기 발견에 혁명을 일으킬 수 있는 잠재력을 가지고 있으며, 임상의는 암, 간 질환, 신경 퇴행성 질환과 같은 질병을 치료 가능성이 높은 초기에 진단할 수 있게 됩니다.

치료에 있어서 당질체학은 보다 표적화되고 효과적인 치료법을 개발할 수 있게 해줍니다. 당쇄 구조는 특히 비정상적인 글리코실화가 관련된 질병에서 약물의 표적이 될 수 있습니다. 예를 들어, 일부 암은 표면 단백질에 특이적인 당쇄 패턴을 보이는데, 당질체학 연구는 이러한 비정상적인 당쇄를 특이적으로 표적으로 하는 치료법을 개발할 수 있도록 돕고 있습니다. 이러한 당쇄를 표적으로 하는 치료는 건강한 조직 손상을 최소화하면서 병변 세포에 초점을 맞추는 보다 정밀한 치료 접근법을 제공합니다. 당질체학은 또한 병원체 및 암세포에 대한 면역 인식을 향상시키는 당쇄 기반 백신의 설계에도 기여하고 있습니다. 당쇄는 면역 체계가 외부 적을 식별하는 데 중요한 역할을 하며, 합성 당쇄를 통합한 백신은 보다 강력하고 특이적인 면역 반응을 유발할 수 있습니다.

당사슬 공학은 단클론 항체, 유전자 치료제, 세포 기반 치료제를 포함한 성장 중인 치료용 생물학적 제제 개발에도 필수적입니다. 치료용 항체와 같은 많은 생물학적 제제는 안정성, 효능 및 안전성을 위해 글리코실화에 의존합니다. 당질체학(Glycomics)는 제조 과정에서 글리코실화 패턴을 이해하고 제어하는 것은 생물학적 제제가 제대로 작동하고 환자에게 안전한지 확인하는 데 매우 중요하며, 당질체학은 제조 과정에서 글리코실화를 모니터링하고 최적화하는 데 필요한 도구를 제공하여 제약사가 보다 효과적이고 일관성 있게 생물학적 제제를 개발할 수 있도록 지원합니다. 보다 효과적이고 일관성 있는 생물학적 제제를 개발할 수 있도록 돕습니다.

치료제와 진단제 외에도 당질체학은 개인 맞춤형 의료의 발전에서 매우 중요한 역할을 하고 있습니다. 당쇄 패턴은 유전적, 환경적 요인에 따라 개인마다 다를 수 있기 때문에 이러한 변화를 이해하면 환자별 당쇄 프로파일에 맞는 맞춤형 치료법을 개발할 수 있습니다. 이는 종양이 종종 특이적인 당쇄 패턴을 보이는 암에서 특히 중요하며, 이는 맞춤 치료의 표적이 될 수 있습니다. 당질체학 분야가 계속 발전함에 따라, 환자 개개인의 분자 프로파일에 맞춘 보다 효과적인 치료를 가능하게 하고, 정밀의료의 미래를 형성하는 데 점점 더 중요한 역할을 하게 될 것으로 보입니다.

당질체학/당쇄생물학 시장의 성장 동력은 무엇일까?

당질체학/당쇄생물학 시장의 급격한 성장에는 맞춤의료에 대한 수요 증가, 의약품 개발의 발전, 복잡한 질병의 유병률 증가, 당쇄 분석의 기술 혁신 등 몇 가지 주요 요인이 있습니다. 첫째, 개인 맞춤형 의료의 추진은 당질체학 시장 성장 촉진요인으로 작용하고 있습니다. 헬스케어가 획일적인 접근 방식에서 보다 맞춤 치료로 전환되고 있는 가운데, 당질체학은 치료의 개별화에 활용할 수 있는 고유한 당쇄 프로파일을 식별하는 도구를 제공합니다. 이는 암세포가 종종 특이적인 당쇄 변화를 보이는 종양학에서 특히 중요하며, 보다 효과적인 치료의 표적이 될 수 있습니다. 질병의 조기 발견과 맞춤 치료 전략을 위해 당쇄 바이오마커를 활용할 수 있다는 점이 연구 및 임상 현장에서 당질체학 기술에 대한 수요를 증가시키고 있습니다.

둘째, 의약품 개발, 특히 생물학적 제제 및 단일 클론 항체 분야의 발전이 당질체학 시장의 성장에 기여하고 있습니다. 많은 생물학적 제제는 활성, 안정성 및 안전성을 위해 당쇄 변형에 의존하고 있으며, 효과적인 치료법을 만들기 위해서는 약물 제조 시 이러한 당쇄 구조를 제어하는 것이 필수적입니다. 제약회사들은 생물학적 제제의 글리코실화를 최적화하고 이러한 치료제가 최고 수준의 효능과 안전성을 충족할 수 있도록 당질체학 도구와 기술에 대한 투자를 늘리고 있습니다. 의약품 개발의 이러한 정밀성에 대한 요구는 제약 산업에서 당질체학의 채택을 촉진하고 있습니다.

셋째, 암, 자가면역질환, 신경퇴행성 질환과 같은 복잡한 질환의 유병률이 증가함에 따라 고급 진단 및 치료 솔루션에 대한 필요성이 증가하고 있습니다. 당질체학은 당쇄의 변화가 질병 진행에 어떻게 관여하는지에 대한 통찰력을 제공함으로써 이러한 수요에 대응할 수 있는 독보적인 위치에 있습니다. 예를 들어, 당쇄 기반 바이오마커는 암의 조기 발견을 위해 개발되고 있으며, 당쇄를 표적으로 하는 치료법은 자가면역질환 및 감염성 질환의 새로운 치료법으로 연구되고 있습니다. 전 세계적으로 이러한 질병에 대한 부담이 계속 증가함에 따라, 당질체학 기반 솔루션에 대한 수요는 크게 증가할 것으로 예상됩니다.

당쇄 분석의 기술 혁신도 당질체학 시장의 성장을 가속하고 있습니다. 질량 분석, 당쇄 어레이 및 생물정보학 도구의 발전으로 연구자들은 더 빠르고, 더 정확하고, 더 높은 해상도로 당쇄를 분석할 수 있게 되었습니다. 이러한 기술을 통해 과학자들은 글리콤을 매핑하고, 질병에 특화된 당쇄 변화를 식별하고, 새로운 당쇄 기반 치료법을 쉽게 개발할 수 있게 되었습니다. 고처리량 당쇄 분석 도구의 가용성이 높아짐에 따라 연구가 가속화되고 진단, 치료, 백신 개발 등의 분야에서 당질체학의 상업적 잠재력이 확대되고 있습니다.

또한, 당질체학 연구에 대한 자금 지원 증가와 전문 당질체학 연구센터의 설립이 시장 성장에 기여하고 있습니다. 정부, 학계, 비상장 기업들은 당질체학 연구에 많은 투자를 하고 있으며, 이는 헬스케어에 변화를 가져올 수 있는 잠재력을 가지고 있기 때문입니다. 학계, 산업계, 의료 서비스 제공업체 간의 협력적 노력으로 당질체학의 임상 적용이 진행되고 있으며, 이는 당질체학 도구 및 기술에 대한 수요를 더욱 촉진하고 있습니다.

결론적으로, 당질체학/당사체 생물학 시장의 성장은 개인 맞춤형 의료에 대한 수요 증가, 의약품 개발의 발전, 복잡한 질병의 유병률 증가, 그리고 당질체학 분석의 기술 혁신에 의해 주도되고 있습니다. 당질체학가 건강과 질병에서 당 사슬의 역할에 대한 더 깊은 통찰력을 제공함에 따라 다양한 의료 및 산업 응용 분야에서 진단, 치료 및 정밀의료의 미래를 형성하는 데 중요한 역할을 하게 될 것입니다.

조사 대상 기업 예시(총 152건)

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 24.10.08

Global Glycomics / Glycobiology Market to Reach US$6.4 Billion by 2030

The global market for Glycomics / Glycobiology estimated at US$2.1 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2023-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 16.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.9 Million While China is Forecast to Grow at 16.0% CAGR

The Glycomics / Glycobiology market in the U.S. is estimated at US$592.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$966.4 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Glycomics / Glycobiology Market - Key Trends and Drivers Summarized

Why Is Glycomics/Glycobiology Emerging as a Key Field in Biotechnology and Medicine?

Glycomics, also referred to as glycobiology, is becoming an essential field in biotechnology and medicine due to its critical role in understanding complex biological processes and advancing therapeutic solutions. But why is glycomics so vital today? Glycomics is the comprehensive study of glycans—complex carbohydrates that attach to proteins and lipids and are involved in a wide variety of biological functions, including cell signaling, immune response, and disease progression. Glycobiology focuses on how these sugar molecules influence cellular communication, disease mechanisms, and the development of new diagnostics and treatments.

The study of glycomics has far-reaching implications for human health, as glycans play a crucial role in the progression of diseases such as cancer, autoimmune disorders, and infections. By decoding the structure and function of glycans, researchers are uncovering new ways to diagnose diseases earlier, develop more targeted therapies, and create more effective vaccines. Moreover, glycomics is critical for understanding drug interactions and designing biologics, which are rapidly becoming essential tools in precision medicine. As the importance of personalized healthcare grows, glycomics is helping to unlock new insights into how the body functions at a molecular level, driving innovation in diagnostics, therapeutics, and vaccine development.

How Are Technological Advancements Accelerating Research and Applications in Glycomics?

Technological advancements are playing a pivotal role in advancing glycomics research, making it possible to decode the complexities of glycans and uncover their diverse functions in biological systems. One significant advancement is the development of high-throughput glycan analysis techniques, such as mass spectrometry (MS) and liquid chromatography (LC), which allow for the rapid identification and characterization of glycan structures. These tools enable researchers to map the glycome—the entire set of glycans in an organism or tissue—faster and with greater accuracy than ever before. This capability is crucial for understanding how glycans differ across tissues, individuals, or disease states, paving the way for more personalized medical treatments.

Another key technological advancement is the application of bioinformatics tools to glycomics research. The complexity of glycan structures, with their numerous branches and diverse configurations, requires sophisticated computational methods for analysis and interpretation. Advances in machine learning and artificial intelligence (AI) are enabling the development of algorithms that can predict glycan structures and their interactions with proteins and lipids. These bioinformatics tools help researchers identify glycan biomarkers for diseases, develop glycan-based therapeutics, and uncover how glycan alterations contribute to disease progression. With AI-driven analytics, scientists can sift through vast amounts of glycomic data to identify patterns and potential therapeutic targets more efficiently.

Advances in synthetic glycobiology are also transforming the field by enabling the design and production of synthetic glycans. These synthetic glycans mimic naturally occurring molecules and are used in vaccine development, drug discovery, and therapeutic research. For instance, researchers can create specific glycan structures to study how pathogens interact with human cells or to develop vaccines that elicit strong immune responses. This capability is particularly important for developing vaccines for complex viruses like influenza and coronaviruses, where glycans play a key role in immune evasion. Additionally, synthetic glycans are being used in the development of glycan-based drugs that target specific receptors on cancer cells or modulate immune responses, opening new avenues for precision medicine.

Another area of advancement is the use of advanced imaging techniques, such as cryo-electron microscopy (cryo-EM) and glycan array technology. These tools allow scientists to visualize how glycans interact with other biomolecules at the molecular level. This is crucial for understanding the role of glycans in processes like cell signaling, pathogen recognition, and immune system function. Glycan arrays, for example, enable the high-throughput screening of glycan interactions with proteins, which can reveal potential drug targets or biomarkers for diseases like cancer and neurodegenerative disorders. These imaging and screening technologies are providing deeper insights into the dynamic role of glycans in health and disease.

Why Is Glycomics Critical for Understanding Disease Mechanisms, Developing Diagnostics, and Advancing Therapeutics?

Glycomics is critical for understanding disease mechanisms, developing diagnostics, and advancing therapeutics because glycans play a fundamental role in regulating biological processes and disease progression. Glycans are involved in nearly every aspect of cellular function, from protein folding and stability to immune system activation and cell-cell communication. Alterations in glycan structures are often associated with disease states, making glycomics an invaluable tool for identifying biomarkers and understanding disease mechanisms at a molecular level.

One of the most important contributions of glycomics to medicine is its ability to uncover biomarkers for early disease detection. Changes in glycosylation—the process by which glycans attach to proteins or lipids—are frequently observed in diseases like cancer, diabetes, and infectious diseases. For example, abnormal glycan patterns are a hallmark of cancer cells, where they can promote tumor growth, metastasis, and immune evasion. By identifying these altered glycan signatures, researchers can develop more sensitive and specific diagnostic tests. Glycan-based biomarkers hold the potential to revolutionize early disease detection, allowing clinicians to diagnose conditions like cancer, liver disease, and neurodegenerative disorders at earlier stages, when treatments are more likely to be effective.

In therapeutics, glycomics is enabling the development of more targeted and effective treatments. Glycan structures can serve as drug targets, particularly in diseases where abnormal glycosylation is involved. For instance, certain cancers exhibit unique glycan patterns on their surface proteins, and glycomics research is leading to the development of therapies that specifically target these aberrant glycans. These glycan-targeting therapies offer a more precise approach to treatment, minimizing damage to healthy tissues while focusing on the diseased cells. Glycomics is also contributing to the design of glycan-based vaccines that enhance immune recognition of pathogens or cancer cells. Glycans play a crucial role in how the immune system identifies foreign invaders, and vaccines that incorporate synthetic glycans can trigger stronger and more specific immune responses.

Glycomics is also essential for the development of biologics, a growing class of therapeutics that includes monoclonal antibodies, gene therapies, and cell-based treatments. Many biologics, such as therapeutic antibodies, rely on glycosylation for their stability, efficacy, and safety. Understanding and controlling glycosylation patterns during drug manufacturing is critical for ensuring that biologics function correctly and are safe for patients. Glycomics provides the tools needed to monitor and optimize glycosylation during production, helping pharmaceutical companies develop more effective and consistent biologic therapies.

In addition to therapeutics and diagnostics, glycomics is playing a pivotal role in advancing personalized medicine. Since glycan patterns can vary between individuals based on genetic and environmental factors, understanding these variations allows for the development of personalized treatments tailored to a patient’s specific glycan profile. This is particularly important in cancer, where tumors often exhibit unique glycosylation patterns that can be targeted with personalized therapies. As the field of glycomics continues to evolve, it will play an increasingly important role in shaping the future of precision medicine, enabling more effective treatments that are customized to individual patients’ molecular profiles.

What Factors Are Driving the Growth of the Glycomics/Glycobiology Market?

Several key factors are driving the rapid growth of the glycomics/glycobiology market, including the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. First, the push toward personalized medicine is a major driver of the glycomics market. As healthcare shifts from a one-size-fits-all approach to more individualized treatments, glycomics offers the tools to identify unique glycan profiles that can be used to tailor therapies. This is particularly important in oncology, where cancer cells often exhibit specific glycan changes that can be targeted for more effective treatments. The ability to use glycan biomarkers for early disease detection and personalized treatment strategies is fueling the demand for glycomics technologies in research and clinical settings.

Second, advancements in drug development, particularly in the field of biologics and monoclonal antibodies, are contributing to the growth of the glycomics market. Many biologic drugs rely on glycosylation for their activity, stability, and safety, and controlling these glycan structures during drug production is essential for creating effective therapies. Pharmaceutical companies are increasingly investing in glycomics tools and technologies to optimize glycosylation in biologics, ensuring that these therapies meet the highest standards for efficacy and safety. This demand for precision in drug development is driving the adoption of glycomics in the pharmaceutical industry.

Third, the growing prevalence of complex diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases, is increasing the need for advanced diagnostic and therapeutic solutions. Glycomics is uniquely positioned to address this need by offering insights into how changes in glycosylation contribute to disease progression. For example, glycan-based biomarkers are being developed for the early detection of cancers, while glycan-targeting therapies are being explored as novel treatments for autoimmune diseases and infectious diseases. As the global burden of these diseases continues to rise, the demand for glycomics-based solutions is expected to grow significantly.

Technological innovations in glycan analysis are also driving the expansion of the glycomics market. Advances in mass spectrometry, glycan arrays, and bioinformatics tools are enabling researchers to analyze glycans with greater speed, accuracy, and resolution. These technologies are making it easier for scientists to map the glycome, identify disease-specific glycan alterations, and develop new glycan-based therapies. The growing availability of high-throughput glycan analysis tools is accelerating research and expanding the commercial potential of glycomics in fields such as diagnostics, therapeutics, and vaccine development.

Additionally, increased funding for glycomics research and the establishment of specialized glycomics research centers are contributing to market growth. Governments, academic institutions, and private companies are investing heavily in glycomics research due to its potential to transform healthcare. Collaborative efforts between academia, industry, and healthcare providers are advancing the application of glycomics in clinical practice, further driving demand for glycomics tools and technologies.

In conclusion, the growth of the glycomics/glycobiology market is being driven by the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. As glycomics continues to provide deeper insights into the role of glycans in health and disease, it will play a crucial role in shaping the future of diagnostics, therapeutics, and precision medicine across a wide range of medical and industrial applications.

Select Competitors (Total 152 Featured) -

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Glycomics / Glycobiology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Interest in Glycomics for Understanding Disease Mechanisms Spurs Market Growth
    • Expansion of Glycobiology in Cancer and Immunology Research Drives Demand
    • Role of Glycomics in Developing Targeted Therapies and Personalized Medicine
    • Market Opportunities in Drug Discovery and Development Utilizing Glycomics
    • Role of Glycomics in Vaccine Development and Infectious Disease Research
    • Consumer Demand for Glycan-based Diagnostics and Biomarkers
    • Expansion of Glycomics in Neurological Research and Neurodegenerative Diseases
    • Role of Glycomics in Enhancing Stem Cell and Regenerative Medicine Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glycomics / Glycobiology Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • JAPAN
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CHINA
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • EUROPE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • FRANCE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • GERMANY
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제